Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis-Reference-Cited by-同舟云学术

Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis

Published:2022-12-20 Issue:12 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Liu Yuanyuan¹,Shi Jin²,Li Lu³,Wu Tuoya⁴,Chu Ping¹,Pang Yu³^ORCID,Guo Yongli¹,Gao Mengqiu²,Lu Jie¹^ORCID

Affiliation:

1. Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, People’s Republic of China

2. Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, People’s Republic of China

3. Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, People’s Republic of China

4. Department of Tuberculosis Diseases, Tongliao Infectious Disease Hospital, Tongliao, Inner Mongolia, People’s Republic of China

Abstract

Delamanid (DLM) and pretomanid (PTM) are recent additions to the anti-tuberculosis (TB) drug armamentarium, and they offer more effective options for drug-resistant TB treatment. In particular, DLM is included in Group C, which is recommended for use in longer multidrug-resistant (MDR)-TB regimens.

Funder

National Natural Science Foundation of China

Beijing Key Clinical Specialty Project

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00531-22

Reference30 articles.

1. WHO. 2020. Global tuberculosis report. World Health Organization, Geneva, Switzerland.

2. WHO. 2020. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis.